Clinical study of remazolam besylate for precise devascularization of esophageal and gastric varices under endoscope in patients with liver cirrhosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046996

Enrollment

Unknown

Registered

2021-06-06

Start date

2021-06-06

Completion date

Unknown

Last updated

2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Group 1:Remazolam besylate

Group 2:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age is 18-65 years old, gender is not limited, ASA II-III, 18<=BMI<=30, precise devascularization of esophagus and gastric varices under elective general anesthesia, operation time 0.5-1 hour, volunteer to participate in the trial And sign the informed consent.

Exclusion criteria

Exclusion criteria: The operation time was > 1h, and the intraoperative hemorrhage was switched to open surgery.

Design outcomes

Primary

Measure	Time frame
Hemodynamics;Intraoperative and postoperative complications;	—

Countries

China

Contacts

Public ContactLiJuan

Anhui Provincial Hospital of the First Affiliated Hospital of University of Science and Technology of China

huamuzi1999@126.com+86 13956974471

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026